Business Context and Reporting Period
This Form 8-K is a current report filed by Oculus Innovative Sciences, Inc. (not Sonoma Pharmaceuticals, Inc.) on September 9, 2016, regarding events occurring on September 2, 2016. The filing details the results of the Company's annual meeting of stockholders held on September 2, 2016.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
Stockholders voted on four proposals at the annual meeting. The total shares entitled to vote were 4,200,756, with 2,989,603 shares present or represented by proxy (including 2,455,235 broker non-votes).
- Proposal 1 (Election of Directors): Mr. Jim Schutz and Dr. Jay Birnbaum were elected as Class II directors.
- Proposal 2 (Executive Compensation): The advisory vote on executive compensation was approved.
- Proposal 3 (Auditor Ratification): The appointment of Marcum LLP as the independent registered public accounting firm for the fiscal year ending March 31, 2017, was ratified.
- Proposal 4 (2016 Equity Incentive Plan): The proposal failed to pass initially, with only 49.35% of votes present voting in favor. Consequently, the meeting was adjourned to September 8, 2016, and subsequently to September 16, 2016, to continue soliciting votes.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business operations. The primary contingency noted is the adjournment of the annual meeting to secure additional votes for the 2016 Equity Incentive Plan.
Important Facts for Investors to Verify
- Verify the final outcome of the 2016 Equity Incentive Plan vote following the adjourned meetings on September 8 and September 16, 2016.
- Confirm the identity of the registrant as Oculus Innovative Sciences, Inc., noting the discrepancy with the requested company name (Sonoma Pharmaceuticals, Inc.).
- Review the definitive proxy statement filed on July 29, 2016, for detailed information on executive compensation and director nominees.